BI 1595043
Alternative Names: BI-1595043Latest Information Update: 28 Jul 2024
Price :
$50 *
At a glance
- Originator Boehringer Ingelheim
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Unspecified in Germany (PO)
- 28 Sep 2023 No recent reports of development identified for phase-I development in Unspecified(In volunteers) in Belgium (PO)
- 15 Mar 2021 Boehringer Ingelheim plans a phase I trial in Healthy volunteers in April 2021 (NCT04789291),